Rapport TherapeuticsRAPP
Recorded

Rapport Therapeutics Stifel 2026 Healthcare Conference

Review the key takeaways and the transcript of this earnings call.

Period 2026Duration24 minParticipants3

Transcript

Preview the first fifteen paragraphs, organized by speaker.

Paul MatteisAnalyst

All right. Thanks very much. Happy to be moderating this fireside chat with the Rapport Therapeutics team. With me is Abe Ceesay, CEO, and Troy Ignelzi, CFO. Maybe I'll just turn it over to Abe and Troy to give a quick update on the company, as it relates to the FOS and now also bipolar program. Maybe, Troy, you could also touch upon the recent financing and cash runway.

Abe CeesayCEO

Great. Paul, thank you so much for the opportunity and the time today. Yes, Rapport Therapeutics, just a quick reminder, a company that is focused on precision neuroscience, leveraging receptor-associated protein science. Our lead program is a TARPγ8 AMPA modulator program. We have always viewed this program as a pipeline in a product opportunity, and that's the strategy that we took from the outset of launching the company. We realized the first step of that pipeline in a product opportunity last year with the release of our phase II data, proof of concept data in focal onset seizures, that really had unprecedented results, one that we think is going to be a very meaningful product for patients in the future. The second indication that we pursued was in bipolar mania.

Abe CeesayCEO

Bipolar mania, just by its inherent characteristics, is a lower probability of success indication from epilepsy, given the lack of preclinical to clinical translation, but one based on our understanding of the biology and mechanistic rationale, we believed in. We've taken the next step with achieving proof of concept in bipolar mania, just about over a little over a month ago. So where we stand today is we see a program that has two shots on goal, high probability of success in terms of translation into phase III, with a multi-billion dollar opportunity across each indication individually.

Troy IgnelziCFO

Yeah, and now, to Paul's question, with that data, we leveraged into a financing that was completed a little over a week ago that has now taken our cash to right around $815 million, which takes us through the end of 2029. Importantly, that gives us an opportunity to complete four phase III proof of concept trials. We'll also have a fifth ongoing with a primary generalized tonic-clonic seizure, which is the second largest of the epilepsy populations. Then we've got some other meaningful milestones coming out, in particular, so a readout of open-label extension data from our phase II that we'll talk about, but also our long-acting injectable program readout in the third quarter of next year. So all of those events are funded.

Paul MatteisAnalyst

Okay, great. Maybe we will jump around and go in the order of proximity of catalysts. This open-label data that is coming out, maybe just set the stage for people in terms of what we should expect in terms of the disclosure, and for you guys, what would be a reaffirming outcome?

Abe CeesayCEO

Sure. As in all open-label extension studies, really the primary goal is safety. We believe that this data is going to be a meaningful safety update for the program in epilepsy. It is important to understand the dynamics of this open-label extension study for RAP-219. This was not the traditional open-label extension study where patients went directly from treatment into an open-label extension study. As a reminder, our phase II study had eight weeks of treatment, eight weeks of washout. Patients were washed out of their drug for eight weeks, and then there was actually a gap between that period and when they rolled into an open-label extension. The reason I say that is that the patient's baseline is going to be completely different from when they enrolled in the treatment period of the phase II study.

Abe CeesayCEO

With that said, we still have re-baselined the patients. We believe that the relative exposures that we are going to be able to report on in the December update will be in the three to six month range, and we will be collecting efficacy data as well. That efficacy data will be defined by both the long episode or electrographic seizure data, but also clinical seizures as well.

Paul MatteisAnalyst

Okay. At this point, on the safety side, if something had emerged that changed your perception of the profile, you would know, right?

Abe CeesayCEO

Yeah, we would. We would know. We monitor all of our trials in a consistent manner for emerging safety or any other issues that one might be looking at as you conduct clinical trials. We believe that this is going to be a really meaningful update as we just think about the overall safety profile for RAP-219.

Paul MatteisAnalyst

Yep. Okay. As it relates to the epilepsy phase III program, maybe talk a little about how that's going in terms of enrollment and execution. I know timelines here are a big focus because of the wide range of analog trials. What's the current thinking there?

Abe CeesayCEO

Yes. We're pleased with the ongoing progress of the phase III program. We have two phase III studies, FOCUS-1 and FOCUS-2. Both have roughly about 320 patients that are looked to be enrolled in each study. As you know, Paul, all of the FOS phase III programs are global in nature. To your point, they do take a while to enroll, just based on kind of the stringent approach one takes to really screening, baseline characteristics, et cetera. For us, we believe there's a few reasons why we can execute these trials in a quality manner as well as do it efficiently. The first and foremost is quality.

Abe CeesayCEO

We believe we have brought kind of the best thinking forward, partnering with groups such as the Epilepsy Study Consortium to really understand that patients are screened appropriately, patients are trained the right way in terms of how they count seizures. From a timing perspective, we've done a couple things. One is we partnered with a company in China to open up China as a country to enroll. Historically, China has not been accessed in phase III programs. Company is a company by the name of Tenacia, which is 100% neuroscience focused in China. The other aspect is really the qualities of the asset as well are super important as you think about enrollment. As it relates to RAP-219, this is a drug that doesn't have drug-drug interactions.

Abe CeesayCEO

We're not competing with any other mechanisms outside of any overlapping AMPA modulators, but that's not a really big issue for us as we think about enrollment. The whole point here is the top of the funnel is much wider than other programs. We're not guiding on delivery of data yet, but we think probably middle of next year we'll be in a position to guide.

Paul MatteisAnalyst

Okay. That's great. I mean, the phase I-B data is, I mean, it's unquestionable, the effect size and the corroboration with the long episodes. I think the only question we think about when we sort of extrapolate to the phase III is, how similar is that phase III population? Is it more heterogeneous? Could that cause some efficacy? What's your perspective overall there?

Abe CeesayCEO

Yeah. I think there's no doubt that the population in phase III will be more heterogeneous. I mean, that's just the nature of going to a broader population. But the heterogeneity, I think, is more defined by the fact that this patient population will not have, or the majority of patients will not have, it'll be probably, if any, a small number of patients would have the RNS device.

FULL TRANSCRIPT

Continue the full translated transcript in StockNow.

Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.

View the full transcript with Pro

Other earnings calls that day

View calls from this day